Marchantia species were
traditionally
used to treat liver failure. Marchantia polymorpha chloroform extract showed a marked hepatoprotective activity in
a dose-dependent manner in paracetamol-induced extensive liver damage
in mice. At a dose of 500 mg/kg (MP-500), it resulted in a reduction
in aspartate transaminase by 49.44%, alanine transaminase by 44.11%,
and alkaline phosphatase by 24.4% with significant elevation in total
proteins by 58.69% with respect to the diseased group. It showed significant
reductions in total bilirubin, total cholesterol, triglycerides, low
density lipoprotein (LDL), very LDL, total lipids, and to high density
lipoprotein ratio (CH/HDL) by 53.42, 30.14, 35.02, 45.79, 34.74, 41.45,
and 49.52%, respectively, together with a 37.69% increase in HDL with
respect to the diseased group. It also showed an elevation of superoxide
dismutase by 28.09% and in glutathione peroxidase by 81.83% in addition
to the reduction of lipid peroxidation by 17.95% as compared to the
paracetamol only treated group. This was further supported by histopathological
examination that showed normal liver architecture and a normal sinusoidal
gap. Metabolic profiling by ultrahigh performance liquid chromatography
coupled with quadrupole time-of-flight mass spectrometer (UHPLC–QTOF/MS)
led to the tentative identification of 28 compounds belonging to phenols,
quinolones, phenylpropanoid, acylaminosugars, terpenoids, lipids,
and fatty acids to which the activity was attributed. Four compounds
were detected in the negative ionization mode which are neoacrimarine
J, marchantin A, chitobiose, and phellodensin F, while the rest were
detected in the positive mode. Thus, it can be concluded that this
plant could serve as a valuable choice for the treatment of hepatotoxicity
that further consolidated its traditional use.